Total amount: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
NON-STANDARD PET NUCLIDES
Hohn A., Zimmermann K., Schaub E., Hirzel W., Schubiger P. A., Schibli R.
Center of Radiopharmaceutical Science Paul Scherrer Institut Villigen PSI, Switzerland
Radioimmuno-positron emission tomography (PET) combined with radioimmunotherapy is attractive to assess tumor targeting and quantitate the radiation dose to tumor and normal tissues. For this purpose, PET radionuclides with adequate physical half-lives matching those of the targeting molecule (e.g. antibodies) are preferable. Copper-64 (T1/2=12.7 h, Eβ+max=653 keV) and Zirconium-89 (T1/2=78.4 d, Eβ+max=901 keV) are attractive isotopes for this purpose. The 72 MeV cyclotron at the Paul Scherrer Institute provides the infrastructure for the production of a wide variety of radionuclides for diagnostic and therapeutic purposes. 64Cu and 89Zr are currently evaluated at the Center for Radiopharmaceu-tical Science (CRS) of the Paul Scherrer Institute (PSI) in combination with the L1 cam targeting antibody chCE7 and various protein formats thereof. A second focus of the CRS is the radiolabeling of small, tumor targeting molecules with technetium. The PET isotope 94mTc offers potential alternative to its widely used 99mTc SPECT counterpart. In this report, the development, optimization and pitfalls of 64Cu, 89Zr and 94mTc production/separation are reported and discussed.